The iconic rise of Viagra has firmly established as a example of pharmaceutical success, but its future within the broader sector now raises questions about long-term yields . Copycat versions are diminishing patent protection , prompting concerns that investing in companies closely tied to Viagra's once-dominant position could be a dangerous move